0.53% Nov 21, 05:11 PM
$0.88 Paid Quarterly
10.5% EPS $8.36
42 years Since 1972
No Ex-Dividend Dates
Have Been Scheduled

BCR - Upcoming Dividend Payouts
Next Ex-Dividend Date None

Amount Declare Date Ex-Dividend Date ▲ Record Date Pay Date Payout Type
No Upcoming Dividend Dates
BCR has not yet officially announced its next dividend payout.

BCR - Dividend Yield & Stock Price History
Current Dividend Yield 0.53%

Arrow-right
5y
All

BCR - Dividend Payout History
Current Annual Payout $0.88

5y
All
Dividend payouts are split-adjusted

BCR - Dividend Growth History

Annualized Growth
1994-2012
Annualized Growth
1994-2004
Annualized Growth
2004-2008
Annualized Growth
2008-2012
Annualized Growth
Last 5 Yrs
Annualized Growth
Last 3 Yrs
Annual
Growth
2012
Consecutive
Years of
Increases
Reveal Dividend Growth History for BCR. 5.4% 5.1% 42 years
Annual dividend amounts based on Ex-dividend date

BCR - Historical Annual Dividend Data & Growth
Payouts Increasing For 42 years

Payout Amount Calendar Year Annual Growth
$0.8200 2013 5.1%
$0.7800 2012 5.4%

BCR - Historical Dividend Data
Payouts Increasing For 42 years

Payout Amount Declared Date Ex-Dividend Date Record Date Pay Date ▼ Qualified Dividend? Payout Type Frequency
$0.2200 2014-10-08 2014-10-16 2014-10-20 2014-10-31 Yes Regular Quarter
$0.2200 2014-06-11 2014-07-17 2014-07-21 2014-08-01 Yes Regular Quarter
$0.2100 2014-04-16 2014-04-24 2014-04-28 2014-05-09 Yes Regular Quarter
$0.2100 2013-12-11 2014-01-16 2014-01-21 2014-01-31 Yes Regular Quarter
$0.2100 2013-10-09 2013-10-17 2013-10-21 2013-11-01 Yes Regular Quarter

C.R. Bard, Inc. (BCR) - News

  • After the bell on Wednesday, a number of big name, dividend paying companies announced their quarterly earnings. Below, we look at these earnings...
  • Over the last month, the S&P 500 Index has shed upwards of 7%; prior to this sell-off, the S&P 500 was up just over 8% for the year. Put...
  • Ex-dividend dates are very important to dividend investors, since you must purchase a stock prior to its ex-dividend date in order to receive its...
  • Ex-dividend dates are very important to dividend investors, since you must purchase a stock prior to its ex-dividend date in order to receive its...
  • Before Wednesday's opening bell, a number of big name dividend stocks were the subject of analyst moves. Below, we highlight the important analyst...
  • After a few weeks of setting record highs, the markets pulled back today, as the World Bank announced a reduction in its global growth forecast. In...
  • After the bell on Tuesday, a few big name, dividend paying companies announced their quarterly earnings. Below, we look at these earnings reports...
  • Citigroup Raises Price Target on C.R. Bard (BCR)

    Citigroup announced on Monday that it has raised its price target on C.R. Bard, Inc. (BCR) from $123.00 to $124.00. The firm also reiterated its Neutral rating on the company. Commenting on the increased price target, Citigroup analyst Mathew J. Dodds noted "We are adjusting our BCR estimates to reflect the continued delay in the Gore court decision and the completion of the Medafor acquisition. We are now assuming a Gore royalty start in 1Q14 and expect the Medafor acquisition to be slightly EPS accretive in 2014. For 3Q13, we have raised our Soft Tissue Repair estimates due to the full US release of Phasix resorbable mesh." C.R. Bard shares traded 1.01% higher during Monday's session. Year-to-date, the stock is up 16.94%.

    The Bottom Line

    Shares of C.R. Bard, Inc. (BCR) currently yield 0.70% based on Monday's closing price of $120.29 and its annual payout of 84 cents. C.R. Bard, Inc. (BCR)  is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

    Expand to read the full story »

  • C.R. Bard to Acquire Rochester Medical for $262 Million (BCR, ROCM)

    C.R. Bard, Inc. (BCR) announced on Wednesday that it will acquire urine drainage care product company, Rochester Medical Corporation (ROCM). BCR will purchase ROCM for about $262 million, or $20 per share. This acquisition will help BCR expand its urology homecare market. The deal is expected to close later this year. C.R. Bard shares were mostly flat during pre-market trading Wednesday. The stock is up 17% YTD. Rochester Medical shares were up $6.04, or 43.74%, during pre-market trading Wednesday. The stock is up 37% YTD. The Bottom Line Shares of C.R. Bard, Inc. (BCR) have a 0.73% yield, based on Tuesday's closing price of $114.66. C.R. Bard, Inc. (BCR) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

    Expand to read the full story »

  • Bank Of America Boosts Price Target on C.R. Bard, Inc. (BCR)

    Bank of America announced on Thursday that it is maintaining its "Buy" rating on the New Jersey-based medical device manufacturer C.R. Bard, Inc. (BCR) , and also went onto raise its price target for the company. Bob Hopkins, an analyst with the bank, noted that they are raising their price target on C.R. Bard following a meeting with the company's CEO and CFO. Hopkins added that C.R. Bard's financial outlook is promising, noting, "BCR remains broadly out of favor, but we see a clear pathway to accelerating growth and upside to numbers and we view the risk reward on near term catalysts as very favorable. BCR trades at 11.8x our view of BCR's potential 2015 cash earnings power and the average medtech company trades at about 12.3x 2015 cash EPS. We argue BCR is an accelerating growth story with a better than average growth outlook, similar risk and near term catalysts." C.R. Bard shares rallied higher on Thursday, gaining 1.37% on the day. The stock is up 18% YTD. The Bottom Line Shares of C.R. Bard, Inc. (BCR) are yielding 0.73% based on Thursday's closing price of $115.71. C.R. Bard, Inc. (BCR) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

    Expand to read the full story »

Top-5-pitch